Results 101 to 110 of about 32,846 (250)

Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets

Brain and Behavior
Objective To investigate the therapeutic effects of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on clinical progression and splenic T‐cell subsets in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis ...
Shuang Song, Bin Li, Ruoyi Guo, Yi Zhou, Yumei Xue, Li Guo   +5 more
doaj   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source

A diabetic patient increased premature ventricular contractions after using liraglutide: a case report

Frontiers in Cardiovascular Medicine
The common adverse reactions of liraglutide are hypoglycemia and gastrointestinal reactions. This case reports a patient with type 2 diabetes mellitus who had an increase in ventricular premature beats after using liraglutide and a decrease in ...
Lilan Huang, He Yu, Ying Fang
doaj   +1 more source

A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs [PDF]

, 2017
Background: Diabetes mellitus is a metabolic disorder defined by high blood glucose. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are a newer class of medications that offer potential 2 to 3 kg weight loss and a 1% to 1.5% decrease in A1c.
Beutel Darrow, Shelby L.
core   +1 more source

Gender-related issues in the pharmacology of new anti-obesity drugs [PDF]

, 2019
Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease.
Barrea, Luigi, Cataldi, Mauro, Colao, Annamaria, Guida, Bruna, Muscogiuri, Giovanna, Savastano, Silvia, Taglialatela, Maurizio   +6 more
core   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory. [PDF]

Compr Physiol
GLP‐1R signaling integrates metabolic state with neural circuits controlling reward, mood, and memory, acting as a metabolic‐cognitive interface. In reward pathways, it suppresses hedonic feeding and drug seeking; in affective circuits, sustained signaling promotes anxiolytic and antidepressant effects; and in the hippocampus, it enhances synaptic ...
Gao SX, Décarie-Spain L, Gu C, Mazzini G, Kanoski SE, Borner T.   +5 more
europepmc   +2 more sources

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. [PDF]

, 2013
BACKGROUND: Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death.
Bergenstal, Richard M, Buse, John B, Daniels, Gilbert H, Frandsen, Kirstine Brown, Mann, Johannes FE, Marso, Steven P, Moses, Alan C, Nauck, Michael A, Nissen, Steven E, Pocock, Stuart, Poulter, Neil R, Ravn, Lasse Steen, Steinberg, William M, Zinman, Bernard   +13 more
core   +2 more sources